<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01653808</url>
  </required_header>
  <id_info>
    <org_study_id>Nipro-Elisio 210H</org_study_id>
    <nct_id>NCT01653808</nct_id>
  </id_info>
  <brief_title>In Vivo Evaluation of the Nipro Elisio™ Dialyzer</brief_title>
  <official_title>In Vivo Evaluation of the Nipro Elisio™ Dialyzer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nipro Europe N.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nipro Europe N.V.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy and biocompatibility of the Nipro Elisio
      210H dialyzer between two dialysis modalities, conventional hemodialysis and on line
      hemodiafiltration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hemodiafiltration, a convective-based therapy combining both diffusive and convective
      transports appears as the treatment modality of choice for hemodialysis patients. Indeed,
      this innovative technique offers an effective dialysis modality removing spectrum of uremic
      solutes with an optimized biocompatibility of the extracorporeal circuit obtained with use of
      ultrapure dialysis and sterile substitution fluids. However, such therapy can not be proposed
      in all dialysis centers due to major drawbacks of this technique over conventional
      hemodialysis, the complexity of the system and its increased costs. Alternatively,
      enhancement of convective transport may now be achieved by use of innovative dialyzers
      allowing more internal filtration. This is the case of ELISIO™-H dialyzers which possess
      fibers of a greater internal length which potentially allow more internal filtration. Aim of
      the present study was therefore to evaluate efficacy and biocompatibility of internal
      filtration-enhanced hemodialysis using this dialyzer compared to hemodiafiltration, over a
      four-month period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pre-dialytic serum beta-2 microglobulin level</measure>
    <time_frame>Month 1 (after one month)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>reduction rate of low molecular weight solutes (urea and creatinine)</measure>
    <time_frame>Month 0, 1, 2, 3, 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>dialysis dose (urea KT/V)</measure>
    <time_frame>Month 0, 1, 2, 3, 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>instantaneous clearance of low molecular weight solutes (urea and creatinine)</measure>
    <time_frame>Month 0, 1, 2, 3, 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammatory markers (CRP, fibrinogen, orosomucoide)</measure>
    <time_frame>month 0, 1, 2, 3, 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammatory marker (interkeukin 6)</measure>
    <time_frame>month 0, 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>nutritional status (albumin, transthyretin, homocysteine)</measure>
    <time_frame>Month 0, 1, 2, 3, 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>endothelial progenitor cells</measure>
    <time_frame>Month 0, 1, 2, 3, 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammatory mononuclear cell activation</measure>
    <time_frame>Month 0, 1, 2, 3, 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>kappa and lambda light chains</measure>
    <time_frame>Month 0, 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>oxidative stress parameters (superoxide anion, AOPPs, AGEs)</measure>
    <time_frame>Month 0, 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>coagulation factors (TFPI, PAI-1, tPA, von willebrand factor and factor VIII)</measure>
    <time_frame>Month 0, 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>apoptosis markers (soluble FAS and FAS ligand)</measure>
    <time_frame>Month 0, 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bone markers (bone PAL, Cross Laps, TRAP5b)</measure>
    <time_frame>Month 0, 4</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Elisio-210H with HD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>hemodialysis patients treated with conventional hemodialysis (HD) modality using Elisio-210H dialyzer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elisio-210H with on line HDF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>hemodialysis patients treated with on line hemodiafiltration (HDF) modality using Elisio-210H dialyzer</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Elisio-210H</intervention_name>
    <description>comparison of efficacy and biocompatibility of Elisio-210H dialyzer between conventional hemodialysis and on line hemodiafiltration</description>
    <arm_group_label>Elisio-210H with HD</arm_group_label>
    <arm_group_label>Elisio-210H with on line HDF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional hemodialysis</intervention_name>
    <description>comparison of conventional hemodialysis with on line hemodiafiltration using Elisio-210H dialyzer</description>
    <arm_group_label>Elisio-210H with HD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>on line hemodiafiltration</intervention_name>
    <description>comparison of on line hemodiafiltration with conventional hemodialysis using Elisio-210H dialyzer</description>
    <arm_group_label>Elisio-210H with on line HDF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CKD dialysis patients on treatment with three times a week HD for more than three
             months

          -  with a stable anticoagulation scheme

          -  with haemoglobin level &gt;10.5 g/dL

          -  with vascular access allowing a stable blood flow of 300 mL/min during treatment

        Exclusion Criteria:

          -  patient already enrolled in another study

          -  pregnancy

          -  symptoms or signs of acute/chronic inflammatory or infectious diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernard CANAUD, MD, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Center of Montpellier, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Center</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 27, 2012</study_first_submitted>
  <study_first_submitted_qc>July 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2012</study_first_posted>
  <last_update_submitted>September 13, 2012</last_update_submitted>
  <last_update_submitted_qc>September 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CKD dialysis</keyword>
  <keyword>hemodialysis</keyword>
  <keyword>hemodiafiltration</keyword>
  <keyword>Elisio dialyzer</keyword>
  <keyword>efficacy</keyword>
  <keyword>biocompatibility</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

